Eli Lilly and Company (NYSE:LLY) Stock Position Lowered by Wolf Group Capital Advisors

Wolf Group Capital Advisors lessened its position in Eli Lilly and Company (NYSE:LLY) by 39.8% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 3,277 shares of the company’s stock after selling 2,163 shares during the period. Eli Lilly and Company makes up 1.2% of Wolf Group Capital Advisors’ holdings, making the stock its 24th largest position. Wolf Group Capital Advisors’ holdings in Eli Lilly and Company were worth $2,967,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. Arrow Financial Corp raised its stake in shares of Eli Lilly and Company by 1.9% in the 2nd quarter. Arrow Financial Corp now owns 8,729 shares of the company’s stock worth $7,903,000 after buying an additional 161 shares in the last quarter. Litman Gregory Wealth Management LLC bought a new stake in shares of Eli Lilly and Company in the 2nd quarter worth $226,000. GoalVest Advisory LLC raised its stake in shares of Eli Lilly and Company by 1.5% in the 2nd quarter. GoalVest Advisory LLC now owns 1,181 shares of the company’s stock worth $1,069,000 after buying an additional 17 shares in the last quarter. TFB Advisors LLC raised its stake in shares of Eli Lilly and Company by 10.7% in the 2nd quarter. TFB Advisors LLC now owns 1,931 shares of the company’s stock worth $1,748,000 after buying an additional 187 shares in the last quarter. Finally, Moloney Securities Asset Management LLC raised its stake in shares of Eli Lilly and Company by 1.5% in the 2nd quarter. Moloney Securities Asset Management LLC now owns 5,362 shares of the company’s stock worth $4,855,000 after buying an additional 78 shares in the last quarter. Institutional investors own 82.53% of the company’s stock.

Analysts Set New Price Targets

LLY has been the topic of a number of recent research reports. Truist Financial restated a “buy” rating and issued a $1,000.00 target price (up from $892.00) on shares of Eli Lilly and Company in a report on Tuesday, June 25th. Jefferies Financial Group lifted their target price on Eli Lilly and Company from $994.00 to $1,015.00 and gave the stock a “buy” rating in a report on Monday, June 24th. Barclays lifted their target price on Eli Lilly and Company from $913.00 to $1,025.00 and gave the stock an “overweight” rating in a report on Wednesday, July 10th. Deutsche Bank Aktiengesellschaft upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating and lifted their target price for the stock from $725.00 to $1,025.00 in a report on Monday, August 12th. Finally, Argus lifted their target price on Eli Lilly and Company from $770.00 to $840.00 and gave the stock a “buy” rating in a report on Tuesday, May 14th. Two investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $961.76.

Insiders Place Their Bets

In other Eli Lilly and Company news, EVP Johna Norton sold 7,056 shares of the company’s stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $819.38, for a total value of $5,781,545.28. Following the transaction, the executive vice president now directly owns 25,428 shares of the company’s stock, valued at approximately $20,835,194.64. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other Eli Lilly and Company news, EVP Johna Norton sold 7,056 shares of the company’s stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $819.38, for a total value of $5,781,545.28. Following the transaction, the executive vice president now directly owns 25,428 shares of the company’s stock, valued at approximately $20,835,194.64. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CAO Donald A. Zakrowski sold 750 shares of the company’s stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $819.47, for a total value of $614,602.50. Following the completion of the transaction, the chief accounting officer now directly owns 7,130 shares in the company, valued at $5,842,821.10. The disclosure for this sale can be found here. Insiders have sold a total of 1,097,883 shares of company stock valued at $972,022,568 in the last three months. Insiders own 0.13% of the company’s stock.

Eli Lilly and Company Stock Performance

Shares of NYSE LLY opened at $960.02 on Friday. The company has a debt-to-equity ratio of 1.90, a current ratio of 1.35 and a quick ratio of 1.03. Eli Lilly and Company has a one year low of $516.57 and a one year high of $972.53. The business’s 50-day moving average price is $891.13 and its two-hundred day moving average price is $819.99. The company has a market capitalization of $912.41 billion, a P/E ratio of 141.39, a price-to-earnings-growth ratio of 1.81 and a beta of 0.41.

Eli Lilly and Company Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 10th. Shareholders of record on Thursday, August 15th will be given a $1.30 dividend. This represents a $5.20 annualized dividend and a yield of 0.54%. The ex-dividend date of this dividend is Thursday, August 15th. Eli Lilly and Company’s payout ratio is currently 76.58%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.